Kaléo Licenses Auto-Injector Tech to Amgen

Kaléo has announced a confidential license agreement with Amgen Inc., allowing Amgen to use certain of Kaléo's patented auto-injector technology. This agreement reflects Kaléo's innovative contribution to drug-device technologies and its leadership in advancing patient-centric auto-injector solutions.

The financial terms of the agreement have not been disclosed, but it is a significant step forward for Kaléo as a global leader in drug-delivery device technology. The company's patented Aerio platform powers its portfolio of auto-injector products and those under development for third parties.